Processing and Ligand-Induced Modifications of the V2 Vasopressin Receptor

  • Hamid M. Sadeghi
  • Giulio Innamorati
  • Evette Esqueda
  • Mariel Birnbaumer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 449)


Synthesis, processing and agonist-induced modifications of the V2 vasopressin receptor were examined in stably or transiently transfected HEK293 cells. Metabolic labeling with35S methionine for 30 min revealed a predominant precursor protein which subsequently gave rise to the mature receptor on the cell surface. Maturation of the receptor was unrelated to glycosylation suggesting that it was the consequence of protein refolding. In addition to monomeric forms of V2 receptor protein, oligomers of the precursor protein were also detected in SDS-PAGE. These oligomers seemed to be dimers and tetrameres, and were more apparent in transiently transfected cells that produced higher quantities of protein then stably transfected cells. No oligomers of the mature receptor were detected, and co-transfection of the wild type with a mutant V2 receptor lacking G-protein coupling activity did not alter the function of the wild type receptor. These results indicated that the formation of oligomeric was most likely a consequence of overproduction of the protein and not a required step for receptor function.

Addition of vasopressin promoted phosphorylation and sequestration of the wild type receptor, and of the R137H mutant receptor which lacks coupling to G proteins. Activation of protein kinases A or C did not result in phosphorylation of un-occupied receptor. Phosphate incorporated into the protein was stable in the continuous presence of the ligand despite sequestration of the receptor protein. Deletion of the last 14 amino acids abolished receptor phosphorylation but not sequestration and desensitization, indicating that these two processes are not dependent on protein phosphorylation. Additionally, phosphorylation and sequestration of the R137H mutant receptor revealed that phosphorylation and sequestration does not require coupling to Gs.


Palmitic Acid Adenylyl Cyclase Activity Nephrogenic Diabetes Insipidus Wild Type Receptor Mature Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. 1992 Molecular cloning of the receptor for human antidiuretic hormone. Nature 357:333–335.PubMedCrossRefGoogle Scholar
  2. 2.
    Lolait SJ, O’Carroll A-M, McBride OW, Konig M, Morel A, Brownstein MJ. 1992 Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357:336–339.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus M-F, Hendy GN, Birnbaumer M, Bichet DG. 1992 Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 359:233–235.PubMedCrossRefGoogle Scholar
  4. 4.
    Pan Y, Metzenberg A, Das S, Gitschier J. 1992 Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nature Genetics 2:103–106.PubMedCrossRefGoogle Scholar
  5. 5.
    van den Ouweland AMW, Dreesen JCFM, Verdijk M, Knoers NVAM, Monnens LAH, Rocchi M, van Oost BA. 1992 Mutations in the vasopressin type 2 receptor gene AVPR2 associated with nephrogenic diabetes insipidus. Nature Genetics 2:99–102.PubMedCrossRefGoogle Scholar
  6. 6.
    Bichet DG, Birnbaumer M, Lonergan M, Arthus M-F, Rosenthal W, Goodyer P, Nivet H, Benoit S, Giampietro P, Simonetti S, Fish A, Whitley CB, Jaeger P, Gertner J, New M, DiBona F, Kaplan BS, Robertson GL, Hendy GN, Fujiwara TM, Morgan K. 1994 Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Huni Gen 55:278–286.Google Scholar
  7. 7.
    Innamorati G, Sadeghi HM, Birnbaumer M. 1996 A fully active non-glycosylated V2 vasopressin receptor. Mol Pharmacol 50:467–473.PubMedGoogle Scholar
  8. 8.
    Sadeghi HM, Innamorati G, Birnbaumer M. 1997 Maturation of Receptor Proteins in Eukaryotic Expression Systems. J Rec Signal Transd Res 17:433–445.CrossRefGoogle Scholar
  9. 9.
    Sadeghi H, Innamorati G, Birnbaumer M. 1997 An X-linked NDI Mutation reveals a requirement for cell surface V2R expression. Mol Endocrinology 11:706–713.CrossRefGoogle Scholar
  10. 10.
    Birnbaumer M, Antaramian A, Themmen APN, Gilbert S. 1992 Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization. J Biol Chem. 267:11783–11788.PubMedGoogle Scholar
  11. 11.
    Hausdorff WP, Caron MG, Lefkowitz RJ. 1990 Turning off the signal: Desensitization of (β-adrenergic receptor function. FASEB J. 4:2881–2898.PubMedGoogle Scholar
  12. 12.
    Innamorati G, Sadeghi H, Eberle AN, Birnbaumer M. 1997 Phosphorylation of the V2 Vasopressin Receptor. J. Biol. Chem. 272:2486–2492.PubMedCrossRefGoogle Scholar
  13. 13.
    Kennelly PJ, Krebs EG. 1991 Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J Biol Chem 266:15555–8.PubMedGoogle Scholar
  14. 14.
    Rosenthal W, Antaramian A, Gilbert S, Birnbaumer M. 1993 Nephrogenic diabetes insipidus: A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem. 268:13030–13033.PubMedGoogle Scholar
  15. 15.
    DebBurman SK, Ptasienski J, Benovic JL, Nosey MM. 1996 G protein-coupled receptor kinase GRK2 is a phospholipid-dependent enzyme that can be conditionally activated by G protein β-gamma subunits. J Biol Chem 271:22552–22562.PubMedCrossRefGoogle Scholar
  16. 16.
    Schuelein R, Liebenhoff U, Mueller H, Birnbaumer M, Rosenthal W. 1996 Properties of the human vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Biochem. J. 313:611–616.Google Scholar
  17. 17.
    Sadeghi H, Innamorati G, Dagarag M, Birnbaumer M. 1997 Role of palmitoylation in V2 vasopressin receptor expression. Mol. Pharmacol, in press.Google Scholar
  18. 18.
    Moffett SW, Mouillac B, Bonin H, Bouvier M. 1993 Altered phosphorylation and desensitization patterns of a human β2-adrenergic receptor lacking the palmitoylated Cys341. EMBO J. 12:349–356.PubMedGoogle Scholar
  19. 19.
    Seibold A, Dagarag M, Birnbaumer M. 1997 Coupling of the 132-adrenergic receptor altered at the DRY motif. Receptors and Channels, in press.Google Scholar
  20. 20.
    Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. 1996 A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Hamid M. Sadeghi
    • 1
  • Giulio Innamorati
    • 1
  • Evette Esqueda
    • 1
  • Mariel Birnbaumer
    • 1
  1. 1.Department of Anesthesiology and Molecular Biology InstituteUniversity of California, Los Angeles School of MedicineLos AngelesUSA

Personalised recommendations